The therapeutic benefits of many psychedelics have been clearly demonstrated through clinical trials, where the use of psilocybin-, ketamine-, and MDMA-assisted psychotherapy showed striking long-term improvements...
In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.
Researchers at Johns Hopkins Medicine have found that just a single psychedelic experience may increase a range of beliefs about consciousness, meaning and purpose.
The Psychedelic Access and European Alliance (PAREA) has launched an appeal to European Union institutions and Member States for psychedelic-assisted therapies in Europe.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...
Germany’s Federal Ministry of Education and Research (BMBF) has provided a grant of €2.6m for a study exploring the efficacy of psilocybin as a treatment for...
Psychedelics venture studio Nucleus has raised USD$135,000 from investors through its Wefunder campaign.
Former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, has been appointed to the role of Executive Special Advisor by Clearmind Medicine.
Data from Diamond Therapeutics’ trial is the first to identify a safe, active and non-psychedelic dosage of psilocybin, which the company says could open the possibility...
BetterLife Pharma has secured investment from Negev Capital and further European investors that will go towards working capital purposes and the advancement of pre-clinical and clinical...